The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Psychotropic medicine consumption in 65 countries and regions, 2008-19: A longitudinal study
Open accessAbstract
Background The WHO Comprehensive Mental Health Action Plan 2013-2030 encourages routine collection and reporting of a set of essential mental health indicators, including the availability of psychotropic medicines. The global monitoring of country-level psychotropic medicine consumption trends can provide information on the extent of the availability of psychotropic medicines. The primary objective of this study was to investigate global trends in psychotropic medicines consumption from 2008 to 2019 across 65 countries and regions according to country income level and geographical region. Methods In this longitudinal trends study, we used pharmaceutical sales data from the IQVIA-Multinational Integrated Data Analysis System (IQVIA-MIDAS). We analysed monthly sales data of psychotropic medicines between Jan 1, 2008, and Dec 31, 2019. Total psychotropic medicine consumption included sales of antidepressants, antipsychotics, tranquilisers, sedatives or hypnotics, and mood stabilisers. Population estimates of each country or region (eight lower-middle-income countries, 19 upper-middle-income countries, and 38 high-income countries) were based on the UN World Population Prospects 2019 report. Average annual sales trends of psychotropic medicines, expressed as defined daily dose (DDD) per 1000 inhabitants per day, were estimated using a random-effects model adjusted for income level and region. Relative changes in the annual consumption of psychotropic medicines by income, expressed as DDD per 1000 inhabitants per day, were assessed as percentage change for each medicine class. Findings Psychotropic medicine sales increased from 28·54 DDD per 1000 inhabitants per day in 2008 to 34·77 DDD per 1000 inhabitants per day in 2019, corresponding to a 4·08% (95% CI 2·96-5·21) relative average increase annually. The absolute annual increase was greater in high-income countries (3·31 DDD per 1000 inhabitants per day, 95% CI 3·01-3·61) compared with upper-middle-income countries (1·94 DDD per 1000 inhabitants per day, 1·45-2·44) and low-middle-income countries (0·88 DDD per 1000 inhabitants per day, 0·62-1·13; p<0·0001). The relative average annual increase in psychotropic medicine sales from 2008 to 2019 was greater in upper-middle-income countries (7·88%, 95% CI 6·99-8·77) than in lower-middle-income countries (2·90%, 2·40-3·39) and high-income countries (1·02%, 0·80-1·24). In 2019, the regional consumption of psychotropic medicines varied greatly, with the highest sales of all psychotropic medicine classes reported in northern America (167·54 DDD per 1000 inhabitants per day) and lowest sales reported in Asia (5·59 DDD per 1000 inhabitants per day). 17 countries had very low consumption of psychotropic medicines in 2019, including high-income countries and countries with a high prevalence of mental disorders. Interpretation The consumption of psychotropic medicines has increased over a 12-year period, and although the absolute growth rate was highest in high-income countries, the relative growth is highest in middle-income countries and especially upper-middle-income countries. Disparities in psychotropic medicine consumption of countries can only partly be explained by geographical location and income. Greater efforts are needed to increase the availability of psychotropic medicines in countries with very low consumption, which is probably due to financial or cultural reasons as well as scarcity of trained health-care professionals to prescribe psychotropic medicines. Funding None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data published in The Lancet indicate that the highest relative growth in psychopharmaceutical use between 2008 and 2019 took place in lower-middle-income countries across the Global South (Brauer et al. 2021).”
From Throwing therapy at the problem mental health and humanitarian intervention in Palabek refugee settlement, northern Uganda (2023) · cites this paper as Brauer et al. 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
No health without mental health
Prince, M. J., Patel, V., Saxena, S., Maj, M., Maselko, J., Phillips, M. R., & Rahman, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61238-0 · Cited by 4,028
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data
Boeckel, T. P. V., Gandra, S., Ashok, A., Caudron, Q., Grenfell, B. T., Levin, S. A., & Laxminarayan, R. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70780-7 · Cited by 2,355
Undertreatment of people with major depressive disorder in 21 countries
Thornicroft, G., Chatterji, S., Evans-Lacko, S., Gruber, M., Sampson, N., Aguilar-Gaxiola, S., Al-Hamzawi, A., Alonso, J., Andrade, L., Borges, G., et al. (2017) · British Journal of Psychiatry · doi:10.1192/bjp.bp.116.188078 · Cited by 1,121
Mental Illness Stigma, Help Seeking, and Public Health Programs
Henderson, C., Evans-Lacko, S., & Thornicroft, G. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301056 · Cited by 959
Mental Health Service Provision in Low- and Middle-Income Countries
Rathod, S., Pinninti, N., Irfan, M., Gorczynski, P., Rathod, P., Gega, L., & Naeem, F. (2017) · Health Services Insights · doi:10.1177/1178632917694350 · Cited by 866
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Alexander, G. C., Gallagher, S. A., Mascola, A. J., Moloney, R., & Stafford, R. S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2082 · Cited by 426
Withdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
International trends in antipsychotic use: A study in 16 countries, 2005–2014
Hálfdánarson, Ó., Zoëga, H., Aagaard, L., Bernardo, M., Brandt, L., Fusté, A. C., Furu, K., Garuolienè, K., Hoffmann, F., Huybrechts, K. F., et al. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.07.001 · Cited by 293
Raman, S. R., Man, K. K. C., Bahmanyar, S., Bérard, A., Bilder, S., Boukhris, T., Bushnell, G., Crystal, S., Furu, K., KaoYang, Y.-H., et al. (2018) · Lancet psychiatry · doi:10.1016/s2215-0366(18)30293-1 · Cited by 285
Self-citationTrends in prescriptions and costs of drugs for mental disorders in England, 1998–2010
Ilyas, S., & Moncrieff, J. (2012) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.111.104257 · Cited by 262
Doi, Y., Minowa, M., Okawa, M., & Uchiyama, M. (2000) · Journal of Epidemiology · doi:10.2188/jea.10.79 · Cited by 258
Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011
Stephenson, C. P., Karanges, E., & McGregor, I. S. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412466595 · Cited by 217
Hsia, Y., Sharland, M., Jackson, C., Wong, I. C. K., Magrini, N., & Bielicki, J. A. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30547-4 · Cited by 206
Self-citationA three-country comparison of psychotropic medication prevalence in youth
Zito, J. M., Safer, D. J., Berg, L. T. D. J.-V. D., Janhsen, K., Fegert, J. M., Gardner, J. F., Glaeske, G., & Valluri, S. C. (2008) · Child and Adolescent Psychiatry and Mental Health · doi:10.1186/1753-2000-2-26 · Cited by 201
Mental health practice in Arab countries
Al‐Krenawi, A. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000179498.46182.8b · Cited by 166
Lewer, D., O'Reilly, C., Mojtabai, R., & Evans-Lacko, S. (2015) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.156786 · Cited by 150
Mental health service provision in low and middle-income countries
Weinmann, S., & Koesters, M. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000256 · Cited by 148
Naveed, S., Waqas, A., Chaudhary, A. M. D., Kumar, S., Abbas, N., Amin, R., Jamil, N., & Saleem, S. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.573150 · Cited by 125
Khong, T. P., de Vries, F., Goldenberg, J. S. B., Klungel, O. H., Robinson, N. J., Ibáñez, L., & Petri, H. (2012) · Calcified Tissue International · doi:10.1007/s00223-012-9603-8 · Cited by 87
Addressing individual behaviours and living conditions: Four Nordic public health policies
Vallgårda, S. (2011) · Scandinavian Journal of Public Health · doi:10.1177/1403494810378922 · Cited by 75
Kurko, T., Saastamoinen, L., Tuulio‐Henriksson, A., Taiminen, T. J., Tiihonen, J., Airaksinen, M., & Hietala, J. A. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4551 · Cited by 73
Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009
Wu, C., Shau, W., Chan, H., Lee, Y., Lai, Y., & Lai, M. (2012) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3255 · Cited by 55
Wong, D. F. K., Cheng, C.-W., Zhuang, X., Ng, T. K., Pan, S.-M., He, X., & Poon, A. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.06.032 · Cited by 54
Evolución del uso de medicamentos ansiolíticos e hipnóticos en España durante el período 2000-2011
Sánchez, M. P. V., Saint-Gerons, D. M., Honrubia, C. D. L. F., Bermejo, D. G., Corominas, D. M., & Catalá-López, F. (2013) · Revista Española de Salud Pública · doi:10.4321/s1135-57272013000300004 · Cited by 45
Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study
Brett, J., Daniels, B. J., Karanges, E. A., Buckley, N. A., Schneider, C. R., Nassir, A., McLachlan, A. J., & Pearson, S. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13369 · Cited by 44
Barczyk, Z. A., Rucklidge, J. J., Eggleston, M. J. F., & Mulder, R. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0032 · Cited by 39
Loggia, G., Attoh-Mensah, E., Pothier, K., Morello, R., Lescure, P., Bocca, M., Marcelli, C., & Chavoix, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01659 · Cited by 39
Time Trend in Psychotropic Medication Use in Spain: A Nationwide Population-Based Study
Carrasco‐Garrido, P., Hernández‐Barrera, V., Jiménez‐Trujillo, I., Esteban‐Hernández, J., Álvaro‐Meca, A., López‐de‐Andrés, A., del-Barrio, J. L., & Jiménez‐García, R. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13121177 · Cited by 26
Depression and Antidepressants: A Nordic Perspective
Vilhelmsson, A. (2013) · Frontiers in Public Health · doi:10.3389/fpubh.2013.00030 · Cited by 24
Cook, M. N. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1309 · Cited by 18
Decreasing Trend in the Use and Long-Term Use of Benzodiazepines Among Young Adults
Tähkäpää, S.-M., Saastamoinen, L., Airaksinen, M. S. A., Tuulio‐Henriksson, A., Aalto‐Setälä, T., & Kurko, T. (2018) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0140 · Cited by 13
International variation in drug usage: An exploratory analysis of the "causes" of variation
Nolte, E., & Corbett, J. (2014) · RAND Corporation eBooks · doi:10.7249/rr899 · Cited by 12
Marković, S. Z., Jovanović, N. I. D., Sedić, B., Vuković, M., Okjan, J. J., Dimitrijević, I., Trikos, L., Mojović, M., & Kastratović, D. A. (2019) · PubMed · Cited by 12
Duration of Antidepressant Treatment
Jenike, M. A. (1997) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879701000409 · Cited by 10
Cited by
Sorted by citations
Ju, C., Wei, L., Man, K. K. C., Wang, Z., Ma, T.-T., Chan, A., Brauer, R., Chui, C., Chan, E., Jani, Y. H., et al. (2022) · Lancet Public Health · doi:10.1016/s2468-2667(22)00013-5 · Cited by 119
Self-citationChan, A. Y. L., Ma, T.-T., Lau, W. C. Y., Ip, P., Coghill, D., Gao, L., Jani, Y. H., Hsia, Y., Wei, L., Taxis, K., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101780 · Cited by 95
Self-citationJiang, T., Wu, W., Ma, M., Hu, Y., & Li, R. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.175664 · Cited by 95
Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study
Chan, A. Y. L., Yuen, A. S. C., Tsai, D. H., Lau, W. C. Y., Jani, Y. H., Hsia, Y., Osborn, D., Hayes, J., Besag, F., Lai, E. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40637-8 · Cited by 75
Self-citationMa, T., Wang, Z., Qin, X. S., Ju, C., Lau, W. C. Y., Man, K. K. C., Castle, D. J., Chang, W. C., Chan, A. Y. L., Cheung, E. C. L., et al. (2023) · SLEEP · doi:10.1093/sleep/zsad124 · Cited by 74
Self-citation
Metadata
- Authors
- Brauer, R., Alfageh, B., Blais, J. E., Chan, E. W., Chui, C. S. L., Hayes, J. F., Man, K. K. C., Lau, W. C. Y., Yan, V. K. C., Beykloo, M. Y., Wang, Z., Wei, L., & Wong, I. C. K.
- Affiliations
- UCL School of Pharmacy (GB)
- King Saud University (SA)
- University of Hong Kong (HK)
- Laboratory of Data Discovery for Health (HK)
- University College London (GB)
- Corresponding author
- Wong, Ian C K
- ORCID
- Venue
- The Lancet Psychiatry
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 8
- Issue
- 12
- Pages
- 1071-1082
- ISSN
- 2215-0366 (ISSN-L)
- PMC
- PMC9766760
- OpenAlex
- W3215716001
- Cited by
- 203
- References
- 39
- Citations by year
- 2026: 55 · 2025: 68 · 2024: 30 · 2023: 31 · 2022: 17 · 2021: 2
- FWCI
- 19.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- National Institute for Health Research
- Amgen
- European Commission
- Bristol-Myers Squibb
- National Health and Medical Research Council
- Pfizer
- National Natural Science Foundation of China
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Hospital Authority
- Novartis
- Food and Health Bureau
- Takeda Pharmaceutical Company
- Innovation and Technology Commission - Hong Kong
- Janssen Pharmaceuticals
- Wellcome Trust (211085/Z/18/Z)
- Research Grants Council, University Grants Committee
- GlaxoSmithKline
- University of Hong Kong
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Psychology › Clinical Psychology › Historical Psychiatry and Medical Practices
- Keywords
- psychotropic drugs, antidepressants, antipsychotic drugs, sedative-hypnotic drugs, mood stabilizers, defined daily doses, drug sales, mental health indicators, country income level, global trends, mental health policy, access to mental health care, mental health funding
- MeSH terms
- Mental Disorders, Drug Utilization, Health Services Accessibility, Humans, Longitudinal Studies, Psychotropic Drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
